Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27743391 | 1.00 | AKR1B1 (0.33) | AKR1B1LMNAL3MBTL1TDP1 | |
| Phosphoric Acid SCHEMBL138688 | 0.88 | AKR1B1 (0.35) | AKR1B1LMNAL3MBTL1TDP1 | |
| Phosphoric Acid SCHEMBL28087875 | 0.88 | AKR1B1 (0.35) | AKR1B1LMNAL3MBTL1TDP1 | |
| Phosphoric Acid SCHEMBL27686073 | 0.88 | AKR1B1 (0.35) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL1198324 | 0.88 | — | — | |
| SCHEMBL97624 | 0.88 | — | — | |
| SCHEMBL22720619 | 0.88 | AKR1B1 (0.41) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL22720618 | 0.88 | AKR1B1 (0.41) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL37362 | 0.88 | — | — | |
| SCHEMBL574324 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617426-A1 | INHIBITOR OF HMGB PROTEIN-MEDIATED IMMUNE RESPONSE ACTIVATION, AND SCREENING METHOD | Japan Science and Technology Agency (JP) | 2013-07-24 | — | — | EP | claimed |
| US-20130183348-A1 | Inhibitor of HMGB Protein-Mediated Immune Response Activation, and Screening Method | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2013-07-18 | — | — | US | claimed |
| WO-2024073386-A1 | IMPLANTABLE MEDICAL DEVICE FOR THE DELIVERY OF A NUCLEIC ACID | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| CN-117479837-A | RNAi nanoparticles and methods of use thereof in agriculture | 耶路撒冷希伯来大学伊萨姆研发有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230027209-A1 | Implantable Medical Device for the Delivery of a Nucleic Acid | CELANESE EVA PERFORMANCE POLYMERS LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230013636-A1 | EXOSOMES-BASED THERAPY FOR LIVER FIBROSIS AND OTHER DISEASES WITH FIBROSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-19 | — | — | US | disclosed |
| CN-115297850-A | Exosome-based treatment for liver fibrosis and other fibrosis-related diseases | 得克萨斯州大学系统董事会 | 2022-11-04 | — | — | CN | disclosed |
| WO-2021113761-A1 | EXOSOMES-BASED THERAPY FOR LIVER FIBROSIS AND OTHER DISEASES ASSOCIATED WITH FIBROSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-2773381-B1 | METHODS OF USING MICRORNA 195 IN PROVIDING NEUROPROTECTION | UNIV KAOHSIUNG MEDICAL (TW) | 2020-06-03 | — | — | EP | disclosed |
| US-10023864-B2 | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta | BERG LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170246200-A1 | MICRORNA-132/212 FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | UNIVERSITé LAVAL (CA) | 2017-08-31 | — | — | US | disclosed |
| WO-2006119266-A2 | HUMAN MICRORNAS AND METHODS FOR INHIBITING SAME | ROCKEFELLER UNIVERSITY (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2005099770-A2 | PANCREATIC ISLET MICRORNA AND METHODS FOR INHIBITING SAME | THE ROCKEFELLER UNIVERSITY (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005097205-A2 | DNA VIRUS MICRORNA AND METHODS FOR INHIBITING SAME | THE ROCKEFELLER UNIVERSITY (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050227934-A1 | Pancreatic islet microRNA and methods for inhibiting same | ROCKEFELLER UNIVERSITY, THE | 2005-10-13 | — | — | US | disclosed |
| US-20050221293-A1 | DNA virus microRNA and methods for inhibiting same | ROCKEFELLER UNIVERSITY, THE | 2005-10-06 | — | — | US | disclosed |
| US-20050222067-A1 | DNA virus microRNA and methods for inhibiting same | THE ROCKEFELLER UNIVERSITY | 2005-10-06 | — | — | US | disclosed |
| US-20050221490-A1 | DNA virus microRNA and methods for inhibiting same | ROCKEFELLER UNIVERSITY, THE | 2005-10-06 | — | — | US | disclosed |
| WO-2005079397-A2 | ANTI-MICRORNA OLIGONUCLEOTIDE MOLECULES | ROCKEFELLER UNIVERSITY (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182005-A1 | Anti-microRNA oligonucleotide molecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246200-A1 | MICRORNA-132/212 FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | TARDBP, RBM12, HTT | AKR1B1 4660/4885LMNA 1428/4885L3MBTL1 112/4885 |
| US-10023864-B2 | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta | HSP90AB1, HSP90AB2P, HSP90AA1 | AKR1B1 711/4885LMNA 2288/4885L3MBTL1 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.